ULO

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Phase 2

A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

Active, not recruitingNCT06891066

Merck Sharp & Dohme LLCHuman Immunodeficiency Virus Type 1 (HIV-1) Infection

Start: 2025-04-14End: 2031-09-30Target: 150Updated: 2025-10-16

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

RecruitingNCT07266831

Merck Sharp & Dohme LLCHuman Immunodeficiency Virus Type 1 (HIV-1) Infection

Start: 2025-12-18End: 2030-04-03Target: 570Updated: 2026-03-27